Logo image
A Comparison of DNA-Binding Drugs as Inhibitors of E2F1− and Sp1−DNA Complexes and Associated Gene Expression
Journal article   Peer reviewed

A Comparison of DNA-Binding Drugs as Inhibitors of E2F1− and Sp1−DNA Complexes and Associated Gene Expression

Shu-Yuan Chiang, Jane Clifford Azizkhan and Terry A Beerman
Biochemistry (Easton), v 37(9), pp 3109-3115
03 Mar 1998
PMID: 9485464

Abstract

In this study, we examined how DNA-binding drugs prevented formation of transcription factor−DNA complexes and influenced gene transcription from the hamster dihydrofolate reductase promoter, which is regulated by E2F1 and Sp1. Gel mobility shift assay data showed that GC-binding drugs (e.g., mitoxantrone) inhibited the DNA binding of both E2F1 and Sp1. In contrast, AT-binding drugs (e.g., distamycin) interfered only with E2F1−DNA complex formation. In an in vitro transcription assay using HeLa nuclear extracts, inhibition of transcription was observed when mitoxantrone or distamycin was added either before or after assembly of the transcription complex on the DNA, although for the latter, higher drug concentrations were needed. Mitoxantrone, which was a stronger inhibitor of transcription factor−DNA complex, was more effective than distamycin at preventing transcript formation. Time course transcription in a cell-free assay with addition of various drug concentrations indicated that high drug concentrations of either mitoxantrone or distamycin completely blocked transcription, while low drug concentrations could delay the synthesis of transcripts.

Metrics

3 Record Views
59 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Biochemistry & Molecular Biology
Logo image